Fred Aslan, Chief Executive Officer at Artiva Biotherapeutics, Inc. (ARTV), sold 23,463 shares at $7.20 ($169K) on 2026-10-06, disclosed to the SEC on 2026-10-07.
Scheduled sale ($169k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ARTV | SELL | 2026-09-04 | $690K | — | Filing → |
| ARTV | SELL | 2026-05-19 | $244K | — | Filing → |
| ARTV | SELL | 2025-12-15 | $19K | — | Filing → |